Since then, additional recurrent mutations have been detected in the Polish population, and now a panel of 10–12 BRCA1/2 variants is commonly used as an initial screening tool for breast and ovarian cancer risk assessments in the population. The gene discussed is BRCA1; the disease is ovarian cancer.